Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-12-06Clinical Trial Update: Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.
Clinical Trial Update discusses evaluating whether measurable residual disease (MRD) status predicts outcomes within a Phase III trial compa…
-
CLINICAL_TRIALS research · 2024-12-06Clinical Trial Update: Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma [Phase 3]
Phase 3 trial comparing continuous versus fixed-duration therapy with daratumumab, lenalidomide, and dexamethasone in relapsed multiple myel…
-
CLINICAL_TRIALS research · 2024-12-06Clinical Trial Update: Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma [Phase 2]
Phase 2 clinical trial of carfilzomib, cyclophosphamide, and dexamethasone with maintenance carfilzomib in multiple myeloma; the study statu…
-
CLINICAL_TRIALS research · 2024-12-03Clinical Trial Update: Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma. [NA]
This document reports on an ongoing clinical trial evaluating vertebroplasty in addition to standard treatment for patients with multiple my…
-
CLINICAL_TRIALS research · 2024-12-03Clinical Trial Update: PRospective Multiple Myeloma Impact Study [NA]
A prospective study investigating outcomes in patients with multiple myeloma, sponsored by SkylineDx, currently active but not recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-11-29Clinical Trial Update: Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
A clinical trial comparing the combination of bortezomib, bendamustine, and melphalan versus melphalan alone for multiple myeloma is current…
-
CLINICAL_TRIALS research · 2024-11-29Clinical Trial Update: A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) [Phase 1, Phase 2]
A Phase 1/2 trial evaluating CC-92480 in combination with standard treatments for relapsed/refractory and newly diagnosed multiple myeloma t…
-
CLINICAL_TRIALS research · 2024-11-27Clinical Trial Update: A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant [Phase 3]
A Phase 3 trial sponsored by Sanofi is evaluating isatuximab with bortezomib, lenalidomide and dexamethasone in adults with newly diagnosed …
-
CLINICAL_TRIALS research · 2024-11-26Clinical Trial Update: A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma
A multicenter cross-sectional study (completed) examining psychological distress, insomnia, and somatic symptoms in patients with multiple m…
-
CLINICAL_TRIALS research · 2024-11-25Clinical Trial Update: Risk Stratification and MRD-driven Maintenance for MM After ASCT [NA]
A recruiting clinical trial from Peking University People's Hospital is investigating risk stratification and MRD-driven maintenance therapy…
-
CLINICAL_TRIALS research · 2024-11-22Clinical Trial Update: Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan [Phase 3]
Phase 3 trial comparing two olanzapine dosing regimens (2.5 mg vs 5 mg) for nausea/vomiting prophylaxis before high-dose melphalan in autolo…
-
CLINICAL_TRIALS research · 2024-11-12Clinical Trial Update: Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
This clinical trial update describes switching patients who are intolerant to bortezomib and newly diagnosed with multiple myeloma to carfil…
-
CLINICAL_TRIALS research · 2024-11-08Clinical Trial Update: A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 1]
A Phase 1 clinical trial evaluating OL-101 injection in relapsed or refractory multiple myeloma is currently recruiting. The study is sponso…
-
CLINICAL_TRIALS research · 2024-11-01Clinical Trial Update: 5p15/ 9q22/ 15q22 Hyperdiploidy and Their Significance in Multiple Myeloma Patients
A clinical trial from Assiut University is investigating the significance of specific hyperdiploidy patterns (5p15, 9q22, 15q22) in patients…
-
CLINICAL_TRIALS research · 2024-10-26Clinical Trial Update: A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma
This document reports a real-world observational study evaluating Zevorcabtagene Autoleucel for relapsed/refractory multiple myeloma, with t…
-
CLINICAL_TRIALS research · 2024-10-26Clinical Trial Update: Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma
A clinical trial evaluating whole body diffusion-weighted MRI (DWI) versus FDG PET/CT in symptomatic multiple myeloma; the study is currentl…
-
CLINICAL_TRIALS research · 2024-10-23Clinical Trial Update: An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia [Phase 1]
Phase 1 exploratory study of RD140 injection in patients with relapsed/refractory multiple myeloma or plasma cell leukemia; the trial is not…
-
CLINICAL_TRIALS research · 2024-10-18Clinical Trial Update: LMY-920 for Treatment of Relapsed or Refractory Myeloma [Phase 1]
Phase 1 clinical trial update for LMY-920 in relapsed or refractory multiple myeloma; recruitment is ongoing by Luminary Therapeutics.
-
CLINICAL_TRIALS research · 2024-10-16Clinical Trial Update: BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating a BCMA-GPRC5D-targeted CAR-T therapy in relapsed or refractory multiple myeloma.
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 study of CM336 in relapsed or refractory multiple myeloma is ongoing and currently recruiting.
-
CLINICAL_TRIALS research · 2024-10-09Clinical Trial Update: Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy [Phase 2]
A Phase 2 clinical trial evaluating an MRD-driven adaptive treatment strategy for newly diagnosed multiple myeloma using upfront daratumumab…
-
CLINICAL_TRIALS research · 2024-10-09Clinical Trial Update: Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Leuko Labs, Inc. is conducting a pivotal study to validate a novel non-invasive system for detecting severe neutropenia. The trial covers Di…
-
CLINICAL_TRIALS research · 2024-10-02Clinical Trial Update: Two Schemes Response in Multiple Myeloma
Clinical trial update describing two treatment schemes showing response in multiple myeloma; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2024-10-01Clinical Trial Update: Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)
This completed non-interventional study in Germany assessed patient and healthcare provider satisfaction with subcutaneous versus intravenou…
-
CLINICAL_TRIALS research · 2024-09-26Clinical Trial Update: Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma [Phase 2]
This clinical trial update describes a Phase 2 study evaluating a combination of selinexor, daratumumab, carfilzomib, and dexamethasone for …